| __timestamp | Novartis AG | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 14993000000 | 305409000 |
| Thursday, January 1, 2015 | 14247000000 | 377080000 |
| Friday, January 1, 2016 | 14192000000 | 432829000 |
| Sunday, January 1, 2017 | 14997000000 | 496079000 |
| Monday, January 1, 2018 | 16471000000 | 557616000 |
| Tuesday, January 1, 2019 | 14369000000 | 658498000 |
| Wednesday, January 1, 2020 | 14197000000 | 770456000 |
| Friday, January 1, 2021 | 14886000000 | 840100000 |
| Saturday, January 1, 2022 | 14253000000 | 944700000 |
| Sunday, January 1, 2023 | 12489000000 | 1136600000 |
| Monday, January 1, 2024 | 12566000000 | 1464300000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two giants: Novartis AG and Vertex Pharmaceuticals Incorporated, from 2014 to 2023.
Novartis AG, a Swiss multinational, consistently reported higher SG&A expenses, peaking in 2018. However, a notable decline of approximately 24% was observed by 2023. In contrast, Vertex Pharmaceuticals, a leader in cystic fibrosis treatments, showcased a steady upward trend, with expenses surging by nearly 272% over the same period.
This divergence highlights differing strategic priorities: while Novartis may be optimizing operations, Vertex is likely investing in growth. Such insights are invaluable for investors and industry analysts aiming to gauge the financial health and strategic direction of these pharmaceutical titans.
Novo Nordisk A/S or Vertex Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
Novartis AG and Sanofi: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Novartis AG vs Bristol-Myers Squibb Company
Comparing SG&A Expenses: Novartis AG vs Gilead Sciences, Inc. Trends and Insights
Comparing SG&A Expenses: Novartis AG vs Cytokinetics, Incorporated Trends and Insights
SG&A Efficiency Analysis: Comparing Novartis AG and Amneal Pharmaceuticals, Inc.
Novartis AG and Vericel Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Vertex Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Regeneron Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Blueprint Medicines Corporation
Vertex Pharmaceuticals Incorporated vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Vertex Pharmaceuticals Incorporated vs Evotec SE: SG&A Expense Trends